Gapping down
In reaction to disappointing earnings/guidance: PODD -7.9%, APOL -5.8%, WDFC -5.7%, BWEN -4.4%, PKE -3%, SIG -1.9%, LB -1.4%, FDO -0.5%
Other news: INFI -11.2% (reports topline results from Phase 2 study of Duvelisib in rheumatoid arthritis; study did not meet primary endpoint), GWPH -7.8% (and Otsuka announce results in first of three Sativex Phase 3 cancer pain trials; primary endpoint did not show a statistically significant difference for Sativex compared with placebo in reducing pain), NBG -6.2% (still checking),AFSI -4.6% (announces the commencement of public offering of 3 mln shares common stock), STML -4.3% (in-licenses novel oral small molecule nuclear transport inhibitor targeting XPO1; Announces Proposed Public Offering of Common Stock; size not disclosed), ALXN -3.7% (reports results from its randomized, open-label, multicenter Phase 2 clinical trial to determine the safety and efficacy of eculizumab in the prevention of antibody mediated rejection), PT -3.5% (still checking), MPW -3.4% (commenced an offering to sell 30 million shares of its common stock in an underwritten public offering ), ARNA -3.1% (modest pullback following yday's 65% gain), SAN -2.5% (Bloomberg TV reporting sources believe Spanish bank considering adding capital, potentially in the multi-billion range), CTRP -1.5% (still checking but may be related to peers PCLN and TRIP dg's), CEMP -0.9% (prices 5.25 shares of common stock at $24.50 per share.
Analyst comments: GPRO -1.9% (cautious tone from Oppenheimer post CES), SAP -1.4% (downgraded to Neutral from Buy at UBS), PCLN -0.9% (downgraded to Hold from Buy at Stifel), NGD -0.8% (downgraded to Sell at ROTH Capital ), COG -0.6% (downgraded to Neutral from Buy at Citigroup), LDOS -0.6% (downgraded to Underweight from Neutral at JP Morgan ), BJRI -0.5% (downgraded to Underweight from Equal-Weight at Morgan Stanley
)
In reaction to disappointing earnings/guidance: PODD -7.9%, APOL -5.8%, WDFC -5.7%, BWEN -4.4%, PKE -3%, SIG -1.9%, LB -1.4%, FDO -0.5%
Other news: INFI -11.2% (reports topline results from Phase 2 study of Duvelisib in rheumatoid arthritis; study did not meet primary endpoint), GWPH -7.8% (and Otsuka announce results in first of three Sativex Phase 3 cancer pain trials; primary endpoint did not show a statistically significant difference for Sativex compared with placebo in reducing pain), NBG -6.2% (still checking),AFSI -4.6% (announces the commencement of public offering of 3 mln shares common stock), STML -4.3% (in-licenses novel oral small molecule nuclear transport inhibitor targeting XPO1; Announces Proposed Public Offering of Common Stock; size not disclosed), ALXN -3.7% (reports results from its randomized, open-label, multicenter Phase 2 clinical trial to determine the safety and efficacy of eculizumab in the prevention of antibody mediated rejection), PT -3.5% (still checking), MPW -3.4% (commenced an offering to sell 30 million shares of its common stock in an underwritten public offering ), ARNA -3.1% (modest pullback following yday's 65% gain), SAN -2.5% (Bloomberg TV reporting sources believe Spanish bank considering adding capital, potentially in the multi-billion range), CTRP -1.5% (still checking but may be related to peers PCLN and TRIP dg's), CEMP -0.9% (prices 5.25 shares of common stock at $24.50 per share.
Analyst comments: GPRO -1.9% (cautious tone from Oppenheimer post CES), SAP -1.4% (downgraded to Neutral from Buy at UBS), PCLN -0.9% (downgraded to Hold from Buy at Stifel), NGD -0.8% (downgraded to Sell at ROTH Capital ), COG -0.6% (downgraded to Neutral from Buy at Citigroup), LDOS -0.6% (downgraded to Underweight from Neutral at JP Morgan ), BJRI -0.5% (downgraded to Underweight from Equal-Weight at Morgan Stanley
)